Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.460
+0.080 (5.80%)
At close: Oct 24, 2025, 4:00 PM EDT
1.440
-0.020 (-1.36%)
After-hours: Oct 24, 2025, 7:32 PM EDT
Biomea Fusion Employees
Biomea Fusion had 106 employees as of December 31, 2024. The number of employees increased by 3 or 2.91% compared to the previous year.
Employees
106
Change (1Y)
3
Growth (1Y)
2.91%
Revenue / Employee
n/a
Profits / Employee
-$1,057,462
Market Cap
103.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 106 | 3 | 2.91% |
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Dec 31, 2021 | 51 | 39 | 325.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BMEA News
- 2 days ago - Biomea Fusion, Inc. (BMEA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript - Seeking Alpha
- 4 days ago - Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series - GlobeNewsWire
- 18 days ago - Biomea Fusion, Inc. - Special Call - Seeking Alpha
- 18 days ago - Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - Benzinga
- 19 days ago - Biomea Fusion Announces Pricing of Public Offering of Securities - GlobeNewsWire
- 19 days ago - Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewsWire
- 19 days ago - Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations - GlobeNewsWire
- 25 days ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire